{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:17:04Z","timestamp":1758845824079,"version":"3.44.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin International"},{"name":"Good Publication Practice","award":["2022;175:1298-1304"],"award-info":[{"award-number":["2022;175:1298-1304"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hereditary hypophosphatemia (HH) is a rare diseases characterized by excessive renal phosphate wasting. Hereditary hypophosphatemia presents as rickets and osteomalacia in children, and osteomalacia in adults. Previous studies have suggested an increased burden of comorbidities and higher risk of early death in individuals with HH compared with controls. This study investigates the comorbidities in HH throughout life and their association with survival compared with controls. Possible HH cases were initially identified from the Danish National Patient Register (DNPR) using diagnostic codes for rickets or hypophosphatemia between 1971 and 2019, and the diagnosis was verified by the review of medical files. A total of 120 individuals with verified HH (case population) were matched by gender, birth year, and month with 50 controls per individual with HH, totaling 6000 controls randomly selected from the Danish Civil Registration System. Comorbidity data related to HH were retrieved from the DNPR. The burden of investigated comorbidities was significantly higher in individuals with HH than controls, with multiple conditions diagnosed and at an earlier age. The lifelong risk of arthrosis was significantly higher and diagnosed earlier in individuals with HH (p\u2009&amp;lt;\u2009.001). By age 50, 31.9% of individuals with HH received their first diagnosis of arthrosis, compared with 4.4% of controls. The lifelong risk of hearing loss was elevated (p\u2009&amp;lt;\u2009.001), often diagnosed by school age, with a rapid increase by age 60. Additionally, risks of hyperparathyroidism and renal failure were higher (both p\u2009&amp;lt;\u2009.001), along with increased rates of hypertensive disease (p\u2009&amp;lt;\u2009.001) and obesity (p\u2009=\u2009.021), with diagnoses increasing from the third decade of life. However, there was no significant increase in ischemic heart disease risk or overall mortality in HH. Further analysis revealed that comorbidities in HH were not associated with a higher risk of death compared with controls with the same conditions.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf143","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:26:33Z","timestamp":1756808793000},"source":"Crossref","is-referenced-by-count":0,"title":["Increased lifelong burden of comorbidities without increased early mortality in hereditary hypophosphatemia: a Danish register study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9217","authenticated-orcid":false,"given":"Signe Sparre","family":"Beck-Nielsen","sequence":"first","affiliation":[{"name":"Centre for Rare Diseases, Department of Pediatrics, Aarhus University Hospital , DK-8200 Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, DK-8200 Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke F\u00e6rgemann","family":"Hansen","sequence":"additional","affiliation":[{"name":"Signum Life Science ApS , DK-2100 Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla Ege","family":"Johansen","sequence":"additional","affiliation":[{"name":"Signum Life Science ApS , DK-2100 Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International , Marlow SL7 ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"7","key":"2025092507513763500_ref1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025092507513763500_ref2","doi-asserted-by":"publisher","first-page":"e0193388","DOI":"10.1371\/journal.pone.0193388","article-title":"Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: novel mutations in PHEX and SLC34A3","volume":"13","author":"Acar","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2025092507513763500_ref3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2025092507513763500_ref4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2025092507513763500_ref5","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025092507513763500_ref6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/jhg.2012.56","article-title":"Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets","volume":"57","author":"Beck-Nielsen","year":"2012","journal-title":"J Hum Genet"},{"issue":"9","key":"2025092507513763500_ref7","doi-asserted-by":"publisher","first-page":"e3021","DOI":"10.1210\/clinem\/dgae868","article-title":"Clinical and molecular genetic characteristics of patients with hereditary hypophosphatemia","volume":"110","author":"Eltan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025092507513763500_ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae203","article-title":"Use of whole-exome sequencing and pedigree analysis to identify X-linked hypophosphatemia in Saudi Arabian families","volume":"9","author":"Al-Hamed","year":"2024","journal-title":"J Endocr Soc"},{"issue":"10","key":"2025092507513763500_ref9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","article-title":"Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review","volume":"32","author":"Giannini","year":"2021","journal-title":"Osteoporos Int"},{"issue":"7","key":"2025092507513763500_ref10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1681\/ASN.2007020143","article-title":"Hypophosphatemia: clinical consequences and management","volume":"18","author":"Brunelli","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2025092507513763500_ref11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/clinem\/dgac488","article-title":"Approach to hypophosphatemic rickets","volume":"108","author":"Ackah","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025092507513763500_ref12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2025092507513763500_ref13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2842.2011.02250.x","article-title":"Periapical and endodontic status of permanent teeth in patients with hypophosphatemic rickets","volume":"39","author":"Andersen","year":"2012","journal-title":"J Oral Rehabil"},{"issue":"3","key":"2025092507513763500_ref14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00223-023-01172-2","article-title":"Disease manifestations and complications in Dutch X-linked hypophosphatemia patients","volume":"114","author":"Bosman","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025092507513763500_ref15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"issue":"2","key":"2025092507513763500_ref16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/joor.13114","article-title":"Oral health-related quality of life in X-linked hypophosphataemia and osteogenesis imperfecta","volume":"48","author":"Gjorup","year":"2021","journal-title":"J Oral Rehabil"},{"issue":"1","key":"2025092507513763500_ref17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2025092507513763500_ref18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2025092507513763500_ref19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"5","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"key":"2025092507513763500_ref20","doi-asserted-by":"publisher","first-page":"1229750","DOI":"10.3389\/fendo.2023.1229750","article-title":"Elevated morbidity and mortality in patients with chronic idiopathic hypophosphatemia: a nationwide cohort study","volume":"14","author":"Kim","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025092507513763500_ref21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1017\/S0022215107001636","article-title":"Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia","volume":"123","author":"Pantel","year":"2009","journal-title":"J Laryngol Otol"},{"issue":"12","key":"2025092507513763500_ref22","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.4443","article-title":"Conductive hearing loss in the Hyp mouse model of X-linked hypophosphatemia is accompanied by hypomineralization of the auditory ossicles","volume":"36","author":"Delsmann","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025092507513763500_ref23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjoto.2016.09.014","article-title":"Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation","volume":"38","author":"Wick","year":"2017","journal-title":"Am J Otolaryngol"},{"issue":"23","key":"2025092507513763500_ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312975","article-title":"Phosphate metabolism and pathophysiology in parathyroiddisorders and endocrine Tumors","volume":"22","author":"Zavatta","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2025092507513763500_ref25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025092507513763500_ref26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/jbmr\/zjae127","article-title":"Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study","volume":"39","author":"Portale","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025092507513763500_ref27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1210\/jcem.75.6.1464657","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025092507513763500_ref28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/EP.12.3.294","article-title":"Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy","volume":"12","author":"McHenry","year":"2006","journal-title":"Endocr Pract"},{"issue":"2","key":"2025092507513763500_ref29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"Makitie","year":"2003","journal-title":"Clin Endocrinol"},{"volume-title":"Comparing the NHS to the Health Care Systems of Other Countries: Five Charts","author":"Mallorie","key":"2025092507513763500_ref30"},{"key":"2025092507513763500_ref31","doi-asserted-by":"publisher","first-page":"101753","DOI":"10.1016\/j.bonr.2024.101753","article-title":"Lessons learned from the real-world diagnosis and management of hereditary hypophosphatemic rickets","volume":"21","author":"Chaturvedi","year":"2024","journal-title":"Bone Rep"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf143\/64189638\/ziaf143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf143\/64189638\/ziaf143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf143\/64189638\/ziaf143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:51:48Z","timestamp":1758801108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf143\/8245722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf143","relation":{},"ISSN":["2473-4039"],"issn-type":[{"type":"electronic","value":"2473-4039"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,2]]},"article-number":"ziaf143"}}